In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
<p>Abstract</p> <p>Background</p> <p>Calculation of individual risk is the cornerstone of effective cardiovascular prevention. <b>arriba</b> is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolut...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-01-01
|
| Series: | BMC Family Practice |
| Online Access: | http://www.biomedcentral.com/1471-2296/14/13 |
| _version_ | 1828472232779710464 |
|---|---|
| author | Diener Annette Celemín-Heinrich Salomé Wegscheider Karl Kolpatzik Kai Tomaschko Katrin Altiner Attila Donner-Banzhoff Norbert Haasenritter Jörg |
| author_facet | Diener Annette Celemín-Heinrich Salomé Wegscheider Karl Kolpatzik Kai Tomaschko Katrin Altiner Attila Donner-Banzhoff Norbert Haasenritter Jörg |
| author_sort | Diener Annette |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Calculation of individual risk is the cornerstone of effective cardiovascular prevention. <b>arriba</b> is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk calculation algorithm currently used in <b>arriba</b> is based on the Framingham risk algorithm calibrated to the German setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care in Germany.</p> <p>Methods/design</p> <p><b>arriba</b>-pro will be conducted within the primary care scheme provided by a large health care insurer in Baden-Württemberg, Germany. Patients who are counseled with <b>arriba</b> by their general practitioners (GPs) will be included in the <b>arriba</b>-pro cohort. Exposure data from the consultation with <b>arriba</b> such as demographic data and risk factors will be recorded automatically by the practice software and transferred to the study centre. Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived from administrative sources.</p> <p>Discussion</p> <p>The study is unique in simulating a therapy naïve cohort, matching exactly research and application setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease who have been excluded from previous studies.</p> <p>Trial registration</p> <p>The study is registered with Deutsches Register Klinischer Studien (DRKS00004633).</p> |
| first_indexed | 2024-12-11T05:26:49Z |
| format | Article |
| id | doaj.art-7a6ca51b7d3a4a2da06fcee258140330 |
| institution | Directory Open Access Journal |
| issn | 1471-2296 |
| language | English |
| last_indexed | 2024-12-11T05:26:49Z |
| publishDate | 2013-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Family Practice |
| spelling | doaj.art-7a6ca51b7d3a4a2da06fcee2581403302022-12-22T01:19:33ZengBMCBMC Family Practice1471-22962013-01-011411310.1186/1471-2296-14-13In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro studyDiener AnnetteCelemín-Heinrich SaloméWegscheider KarlKolpatzik KaiTomaschko KatrinAltiner AttilaDonner-Banzhoff NorbertHaasenritter Jörg<p>Abstract</p> <p>Background</p> <p>Calculation of individual risk is the cornerstone of effective cardiovascular prevention. <b>arriba</b> is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk calculation algorithm currently used in <b>arriba</b> is based on the Framingham risk algorithm calibrated to the German setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care in Germany.</p> <p>Methods/design</p> <p><b>arriba</b>-pro will be conducted within the primary care scheme provided by a large health care insurer in Baden-Württemberg, Germany. Patients who are counseled with <b>arriba</b> by their general practitioners (GPs) will be included in the <b>arriba</b>-pro cohort. Exposure data from the consultation with <b>arriba</b> such as demographic data and risk factors will be recorded automatically by the practice software and transferred to the study centre. Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived from administrative sources.</p> <p>Discussion</p> <p>The study is unique in simulating a therapy naïve cohort, matching exactly research and application setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease who have been excluded from previous studies.</p> <p>Trial registration</p> <p>The study is registered with Deutsches Register Klinischer Studien (DRKS00004633).</p>http://www.biomedcentral.com/1471-2296/14/13 |
| spellingShingle | Diener Annette Celemín-Heinrich Salomé Wegscheider Karl Kolpatzik Kai Tomaschko Katrin Altiner Attila Donner-Banzhoff Norbert Haasenritter Jörg In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study BMC Family Practice |
| title | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
| title_full | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
| title_fullStr | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
| title_full_unstemmed | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
| title_short | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
| title_sort | in vivo validation of a cardiovascular risk prediction tool the arriba pro study |
| url | http://www.biomedcentral.com/1471-2296/14/13 |
| work_keys_str_mv | AT dienerannette invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT celeminheinrichsalome invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT wegscheiderkarl invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT kolpatzikkai invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT tomaschkokatrin invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT altinerattila invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT donnerbanzhoffnorbert invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT haasenritterjorg invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy |